Jump to content

Biotechnology patent applications on 7th August 2025

From WikiPatents

Biotechnology Patent Applications on 7th August 2025

Executive Summary

On 7th August 2025, 152 patent applications related to Biotechnology were published, representing 2.2% of all patent applications for the day. This moderate level of activity shows Biotechnology is gaining significant attention from innovators.

Market Analysis

Leading Organizations

The top organizations driving Biotechnology innovation include:

Template:Newsletter signup box

These 5 organizations account for 25 applications (16.4% of all Biotechnology patents), indicating a diverse and competitive landscape.

Technology Deep Dive

Core Innovation Areas

Patent applications in Biotechnology encompass several key innovation areas:

Technical Classification Analysis

The most active CPC classifications in Biotechnology include:

  • C12N15/86 (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media): 22 applications (14.5%)
  • C12N15/113 (Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants): 21 applications (13.8%)
  • C12N2310/20 (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media): 18 applications (11.8%)
  • C12N9/22 (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media): 16 applications (10.5%)
  • C12N2310/11 (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media): 13 applications (8.6%)
  • C12N2310/14 (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media): 12 applications (7.9%)
  • C12N15/85 (for animal cells): 12 applications (7.9%)
  • C12N15/11 (DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology,): 12 applications (7.9%)
  • C12N2750/14143 (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media): 12 applications (7.9%)
  • C12N2310/315 (of the backbone): 11 applications (7.2%)

Global Innovation Landscape

Innovation in Biotechnology spans multiple countries:

  • US: 403 inventors (64.6%)
  • CN: 64 inventors (10.3%)
  • JP: 27 inventors (4.3%)
  • DE: 21 inventors (3.4%)
  • FR: 17 inventors (2.7%)
  • SE: 17 inventors (2.7%)
  • GB: 9 inventors (1.4%)
  • CA: 9 inventors (1.4%)
  • CH: 8 inventors (1.3%)
  • NL: 7 inventors (1.1%)

The US accounts for 64.6% of inventors in Biotechnology, indicating strong domestic innovation leadership.

Industry Collaborations

Notable collaborations in Biotechnology include:

These collaborations represent 16 joint applications, indicating moderate industry cooperation in Biotechnology.

Leading Inventors

Key inventors driving Biotechnology innovation:

Recent Patent Applications

Representative Biotechnology patent applications from 7th August 2025:

20250248376. METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES CAUSED BY A CNTNAP1 MUTATION

Applicant: Board of Regents The University of Texas System

Abstract: Disclosed herein are methods and compositions useful in treating a neuropathy caused by a CNTNAP1 mutation. Transgenic animal models and cell lines are disclosed for the study of neuropathies caused by a CNTNAP1 mutation. Methods of screening and identifying active agents for the treatment of neuropathies caused by a CNTNAP1 mutation are also provided.

20250248377. NON-HUMAN ANIMALS HAVING A HUMANIZED TSLP GENE, A HUMANIZED TSLP RECEPTOR GENE, AND/OR A HUMANIZED IL7RA GENE

Applicant: Regeneron Pharmaceuticals Inc

Abstract: Disclosed herein are rodents (such as, but not limited to, mice and rats) genetically modified to comprise a humanized Tslp gene, a humanized Tslpr gene, a humanized Il7ra gene, or a combination thereof. Compositions and methods for making such genetically modified rodents, as well as methods of using such genetically modified rodents as an animal model for diseases such as allergic diseases and cancer are provided.

20250248378. TRANSGENIC ANIMALS FOR MERCURY BIOREMEDIATION

Applicant: Macquarie University

Abstract: There is provided a transgenic animal comprising heterologous nucleic acid encoding a bacterial organomercurial lyase and/or a bacterial mercuric reductase, wherein the transgenic animal expresses the bacterial organomercurial lyase and/or a bacterial mercuric reductase to reduce the toxicity of a mercury compound.

20250248379. piRNA-BASED CONSTRUCTS FOR REGULATING GENE EXPRESSION AND METHODS OF USE THEREOF

Applicant: Rutgers The State University of New Jersey

Abstract: This disclosure is based, in part, on the unexpected discovery that a piRNA-based construct is able to silence genes that are essential for transmission and/or infection of pathogens. The disclosed constructs and methods of use thereof capitalize on the role piRNAs play in transcriptional silencing and general immunity and enable development of transgenic approaches to inhibit transmission of human and crop diseases.

20250248406. NOVEL INSECT INHIBITORY PROTEINS

Applicant: Monsanto Technology LLC

Abstract: Pesticidal proteins exhibiting inhibitory, suppressive, and toxic activity against Lepidopteran pest species are disclosed, and include, but are not limited to, TIC4064 and TIC4064 amino acid sequence variants. DNA constructs are provided which contain a recombinant nucleic acid sequence encoding one or more of the disclosed pesticidal proteins. Transgenic plants, plant cells, seed, and plant parts resistant to Lepidopteran infestation are provided which contain recombinant nucleic acid sequence...

Market Implications

Innovation Intensity

With 152 applications in a single day, Biotechnology demonstrates very high innovation intensity, suggesting rapid technological advancement and strong commercial interest.

Competitive Landscape

Innovation in Biotechnology involves 142 organizations, indicating a highly competitive and diverse landscape with many players investing in R&D.

Technology Outlook

Emerging themes in Biotechnology patents include: methods, nucleic, cells, compositions, that, suggesting future development in these areas.

The current patent activity level suggests Biotechnology is in a growth phase with increasing market adoption and investment.

Related Technology Areas

Innovation in Biotechnology often intersects with other emerging technologies:

Analysis Tools

Search Resources

See Also

Retrieved from "https://wikipatents.org/index.php?title=Biotechnology_patent_applications_on_7th_August_2025&oldid=671064"
Cookies help us deliver our services. By using our services, you agree to our use of cookies.